4D Molecular Therapeutics, Inc. (FDMT) — SEC Financial Statements & Analysis

4D Molecular Therapeutics, Inc. (FDMT) is a biological products, (no diagnostic substances) company, incorporated in DE. 4D Molecular Therapeutics, Inc. trades on Nasdaq as: FDMT. 4D Molecular Therapeutics, Inc. (FDMT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, 4D Molecular Therapeutics, Inc. carries a market cap of $934.62M, a P/E ratio of -5.22x, a P/B ratio of 2.29x, a P/S ratio of 10.16x, an enterprise value of $883.83M, and an EV/EBITDA multiple of -4.60x. On profitability, it posts an operating margin of -214.24%, a net margin of -194.74%, a Return on Equity (ROE) of -43.25%, a Return on Assets (ROA) of -37.09%, and a Return on Invested Capital (ROIC) of -56.12%. Per share, it reports EPS of $-2.55, diluted EPS of $-2.55, free cash flow per share of $-2.22, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 278712.12% year-over-year, net income growth of -8.65% year-over-year, and EPS growth of -27.30% year-over-year. On the balance sheet, it maintains a current ratio of 8.03x, a quick ratio of 7.68x, working capital of $335.28M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.17, free cash flow of $-156.29M (TTM), and net debt of $-50.78M. Figures sourced from SEC EDGAR.

Market Cap

$934.62M

P/E TTM

-5.22x

EPS TTM

$-2.55

P/B TTM

2.29x

ROE TTM

-43.25%

ROA TTM

-37.09%

Debt To Equity

0.21x

Free Cash Flow TTM

$-156.29M

Net Revenue TTM Growth 1Y

278712.12%

Data as of 2026-06-30 · Source: SEC EDGAR